10th Anniversary Conference Of The British HIV Association [BHIVA] 15 – 17 April 2004, City Hall, Cardiff, UK

[AUTHOR(S):] W Bannister¹, J Gatell², O Kirk³, A Phillips¹, A Mocroft¹, J Lundgren^3
1 Royal Free and University College Medical School, London, UK; ² Hospital Clinic I Provincial, Barcelona, Spain; ³ Copenhagen HIV Programme, Hvidovre Hospital, Denmark

BHIVA Conf 2004 Apr 15-17;10:O16

BACKGROUND: Decreasing response rates to HAART over time may suggest the emergence of primary resistance while regional variation may identify differences in the use of available agents. This study was designed to determine whether any improvements in the response to HAART have been consistent across regions of Europe.

METHODS: We studied 1713 antiretroviral-naïve patients who started HAART (≥3 drugs including protease inhibitor/non-nucleoside reverse transcriptase inhibitor/abacavir) with a viral load (VL) of >400 HIV-1 RNA copies/ml. Response was assessed as the first VL 6–12 months after starting HAART ≤400 copies/ml), stratified by region and year started HAART (early 1996–1997, mid 1998–1999, late 2000–2002).

RESULTS: Only small improvements in response were observed in later years, more especially in northern and eastern regions, despite new antiretrovirals and better toxicity management.

PRESENTING AUTHOR: W Bannister

Download Presentation

040415
O16

Copyright © 2004 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD